All data are based on the daily closing price as of July 9, 2025
d

Daewoong pharmaceutical

069620.KO
118.22 USD
5.75
+5.11%

Overview

Last close
118.22 usd
Market cap
1.36B usd
52 week high
122.67 usd
52 week low
72.15 usd
Target price
146.68 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
1.2922
Price/Book Value
2.2019
Enterprise Value
1.70B usd
EV/Revenue
1.6171
EV/EBITDA
18.6628

Key financials

Revenue TTM
1.05B usd
Gross Profit TTM
541.54M usd
EBITDA TTM
148.04M usd
Earnings per Share
N/A usd
Dividend
0.44 usd
Total assets
1.35B usd
Net debt
N/A usd

About

Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. Daewoong Pharmaceutical Co., Ltd. has a collaboration agreement with Salipro Biotech AB for the use of Salipro platform for stabilizing challenging membrane proteins to advance drug discovery. The company was founded in 1945 and is headquartered in Seoul, South Korea.
  • Symbol
    069620.KO
  • Exchange
    KO
  • Isin
    KR7069620003
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Seng-Ho Jeon
  • Headquarter
    Seoul
  • Web site
    https://www.daewoong.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top